AccessibilityHelp

Most Active Stocks Daily Stock Gainers Daily Stock Losers

Most Active Stocks Daily Stock Gainers Daily Stock Losers

Brian Orelli, PhD

TMFBiologyFool

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Articles by Brian Orelli, PhD — Page 197

The FDA Leaves Pfizer in the Waiting Room

Mar 25, 2009 by Brian Orelli, PhD

The FDA Leaves Pfizer in the Waiting Room

The EU loves its new osteoporosis drug, but what about the U.S.?

Wyeth: Now Approved to Kill More Bugs!

Mar 25, 2009 by Brian Orelli, PhD

Wyeth: Now Approved to Kill More Bugs!

Wyeth's antibiotic gets approved for another indication.

Taking the F Out of FDA

Mar 24, 2009 by Brian Orelli, PhD

Taking the F Out of FDA

Would that result in a D or an A grade?

Which Pharmas Still Have Cash?

Mar 23, 2009 by Brian Orelli, PhD

Which Pharmas Still Have Cash?

There's plenty left to be spent.

Good News for Eli Lilly's Depression Drug

Mar 23, 2009 by Brian Orelli, PhD

Good News for Eli Lilly's Depression Drug

An expanded label is approved for its combo pill.

No More Tears, Far More Fears?

Mar 20, 2009 by Brian Orelli, PhD

No More Tears, Far More Fears?

Sorry, China -- carcinogens in baby shampoo don't equal lead in toys.

EU to Gilead: More Trials for You

Mar 20, 2009 by Brian Orelli, PhD

EU to Gilead: More Trials for You

The U.S. isn't ready for this drug, and neither is Europe.

One Down, One to Go

Mar 19, 2009 by Brian Orelli, PhD

One Down, One to Go

Sanofi-aventis slides past an FDA panel and hopes for more good news today

Teva: An Equal-Opportunity Bully

Mar 19, 2009 by Brian Orelli, PhD

Teva: An Equal-Opportunity Bully

Making money by picking on the little guy, too.

Johnson & Johnson and Shakespeare

Mar 18, 2009 by Brian Orelli, PhD

Johnson & Johnson and Shakespeare

The stage is set for a dramatic decision.

Merck Pummels Pfizer

Mar 18, 2009 by Brian Orelli, PhD

Merck Pummels Pfizer

One of these acquisitions is not like the other.

Stent Wars, Episode III: The Rise of Xience V

Mar 17, 2009 by Brian Orelli, PhD

Stent Wars, Episode III: The Rise of Xience V

Johnson & Johnson lost the lead, but this is a marathon, not a footrace.

Will the New FDA Chief Make Your Investments Healthy?

Mar 16, 2009 by Brian Orelli, PhD

Will the New FDA Chief Make Your Investments Healthy?

It's not Steven Nissen, so that's got to be a good sign.

Pfizer Finally Gets a Hit!

Mar 13, 2009 by Brian Orelli, PhD

Pfizer Finally Gets a Hit!

Positive results on cancer drug come earlier than expected.

Will These Drugs Get Past the FDA?

Mar 13, 2009 by Brian Orelli, PhD

Will These Drugs Get Past the FDA?

March madness, biotech style.

2 Suitors Are Better Than 1

Mar 12, 2009 by Brian Orelli, PhD

2 Suitors Are Better Than 1

Drug company acquisitions prove competition benefits shareholders.

Another Test of Trust

Mar 11, 2009 by Brian Orelli, PhD

Another Test of Trust

Drug companies and patients get hurt when data might not be reliable.

So Much Potential, So Little Growth

Mar 10, 2009 by Brian Orelli, PhD

So Much Potential, So Little Growth

Acquisitions catch up to American Oriental Bioengineering.

Merck-Schering Trumps Pfizer-Wyeth

Mar 9, 2009 by Brian Orelli, PhD

Merck-Schering Trumps Pfizer-Wyeth

Looking at this deal from several viewpoints, it's just better all around.

Why the Buyback, Intuitive Surgical?

Mar 6, 2009 by Brian Orelli, PhD

Why the Buyback, Intuitive Surgical?

Buybacks for high-growth companies aren't such a bad idea anymore.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services